DoW Toxic Exposures Translational Research Award
Summary: The intent of the fiscal year 2026 (FY26) Toxic Exposures Research Program (TERP) Translational Research Award (TRA) is to support translational research that will accelerate the movement of promising ideas in military-related toxic exposure research into clinical applications, including health care products, interventions, technologies and/or clinical practice guidelines. Offered by Defense Health Agency Contracting Activity - DHACA; awards $6.0M; applications due November 19, 2026.
Key Facts
- Funder
- Defense Health Agency Contracting Activity - DHACA
- Award amount
- $6.0M
- Deadline
- November 19, 2026
- Geography
- United States
- Categories
- Research
- Status
- Open
About This Grant
Summary: The intent of the fiscal year 2026 (FY26) Toxic Exposures Research Program (TERP) Translational Research Award (TRA) is to support translational research that will accelerate the movement of promising ideas in military-related toxic exposure research into clinical applications, including health care products, interventions, technologies and/or clinical practice guidelines. Translational research may be defined as an integration of basic science and clinical observations. New Approach...
Full requirements and application instructions: official listing.
Similar Open Grants
DoW Neurofibromatosis Investigator-Initiated Research Award
Defense Health Agency Contracting Activity - DHACA
DoW Neurofibromatosis Research Academy – Scholar Award
Defense Health Agency Contracting Activity - DHACA
DoW Neurofibromatosis Exploration-Hypothesis Development Award
Defense Health Agency Contracting Activity - DHACA
DoW Neurofibromatosis Synergistic Idea Award
Defense Health Agency Contracting Activity - DHACA
DoW Duchenne Muscular Dystrophy, Clinical/Translational Research Award
Defense Health Agency Contracting Activity - DHACA
DOW Combat Readiness – Medical Research Program Translational Research Award
Defense Health Agency Contracting Activity - DHACA
NIH StrokeNet Clinical Trials and Biomarker Studies for Stroke Treatment, Recovery, and Prevention (UG3/UH3 Clinical Trial Optional)
National Institutes of Health
Seamless Early-Stage Clinical Drug Development (Phase 1 to 2a) for Novel therapeutic Agents for the Spectrum of Alzheimer's Disease (AD) and AD-related Dementias (ADRD) (UG3/UH3 Clinical Trial Required)
National Institutes of Health
HEAL Initiative: Pain Research Enhancement Program (PREP) (R15 Clinical Trial Optional)
National Institutes of Health
Competing Revisions to Existing NIH Single Project Research Grants and Cooperative Agreements (Clinical Trial Optional)
National Institutes of Health